<DOC>
	<DOCNO>NCT02035800</DOCNO>
	<brief_summary>Broca II prolongation original study name BROCA . In BROCA study , 25 patient participate enough conclude clearly hypothesis .</brief_summary>
	<brief_title>Bone Resorption , Osteoclastogenesis Adalimumab</brief_title>
	<detailed_description>Osteoclasts ( OC ) clearly involve joint destruction Rheumatoid Arthritis ( RA ) , show clinical experimental data . Tumor Necrosis Factor Alpha ( TNF-alpha ) , major pathologic mediator RA , may induce bone resorption either directly , stimulate osteoclastogenesis indirectly , influence receptor activator nuclear factor kappa-B ligand ( RANKL ) , osteoprotegerin ( OPG ) prostaglandin production osteoblast . Anti-TNF agent reduce bone destruction RA effect osteoclast biology patient RA little know . The original BROCA study , include cohort 25 RA patient , aim study effect treatment Adalimumab time zero , 3 6 month follow osteoclastic parameter : 1 ) number osteoclast precursor ( CD14+ ) cell peripheral blood , 2 ) number osteoclast generate vitro , 3 ) amount bone resorption vitro , 3 6 month treatment Adalimumab . The secondary outcome 1 ) The effect treatment Adalimumab disease activity score define DAS28 score ( Disease Activity Score , 2 ) The effect treatment Adalimumab ( also name : Humira ) change functional status health assessment questionnaire ( HAQ ) , 3 ) Parallel vitro differentiation assay ( number osteoclast generate amount bone resorption ) presence exogenous Adalimumab concentration range find plasma treated patient detect direct effect medication vitro osteoclastogenesis . The result show treatment Adalimumab induce statistically significant reduction clinical score DAS28 HAQ , show many clinical study . Even though statistically significant effect treatment find number osteoclast precursor , number osteoclast generate vitro surface bone resorption vitro , clear trend towards decrease last two parameter . We believe lack statistical significance due type II error , consequence much high variance primary parameter ( number vitro-generated osteoclast ) patient cohort could foresee initial data normal donor . Moreover , statistically significant correlation ( p=0.416 , linear regression ) difference number osteoclast time zero six month difference HAQ score , support hypothesis treatment Adalimumab may associate reduction number osteoclast also suggest reduction may associate good response treatment . The general objective propose prolongation BROCA study verify two work hypothesis .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Bone Resorption</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Patients age 18 , Satisfying 1987 American College Rheumatology ( ACR ) criteria RA Receiving prescription Adalimumab 40 mg subcutaneous every two week . Patients capable willing provide inform consent Patients start Adalimumab less five halflives interruption previous antiTNF therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Adalimumab</keyword>
	<keyword>Humira</keyword>
</DOC>